Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma-Reply

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
² Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

Comment

Andrea Cercek et al. JAMA Oncol. 2020.

. 2020 Jun 1;6(6):935-936.

doi: 10.1001/jamaoncol.2020.0343.

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
² Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

No abstract available

Comment on

Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Cercek A, Boerner T, Tan BR, Chou JF, Gönen M, Boucher TM, Hauser HF, Do RKG, Lowery MA, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Schultz N, Kingham TP, D'Angelica MI, DeMatteo RP, Drebin JA, Allen PJ, Balachandran VP, Lim KH, Sanchez-Vega F, Vachharajani N, Majella Doyle MB, Fields RC, Hawkins WG, Strasberg SM, Chapman WC, Diaz LA Jr, Kemeny NE, Jarnagin WR. Cercek A, et al. JAMA Oncol. 2020 Jan 1;6(1):60-67. doi: 10.1001/jamaoncol.2019.3718. JAMA Oncol. 2020. PMID: 31670750 Free PMC article. Clinical Trial.
Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma.
Yang X, Pan J, Zhao H. Yang X, et al. JAMA Oncol. 2020 Jun 1;6(6):935. doi: 10.1001/jamaoncol.2020.0340. JAMA Oncol. 2020. PMID: 32271359 No abstract available.